Inventor · disambiguated record
Kerry Louise Tyson
Also filed as: TYSON KERRY LOUISE
38 granted patents·25 pending applications·636 citations·filing 2001–2025
97Inventor score
Files withUCB Biopharma SRL19UCB BIOPHARMA SPRL17UCB PHARMA SA5HARVARD COLLEGE4OXFORD GLYCOSCIENCES UK LTD2
Top patents by PatentIndex Score
63 records- 0198US8927697B2PD-1 specific antibodies and uses thereofDAVIS SIMON·Filed 2009·Granted Jan 6, 2015·205 cites·10 claims
- 0297US10590197B2Antibody molecules which bind CD22UCB BIOPHARMA SPRL·Filed 2016·Granted Mar 17, 2020·14 cites·7 claims
- 0397US8993731B2PD-1 antibodyTYSON KERRY LOUISE·Filed 2011·Granted Mar 31, 2015·186 cites·17 claims
- 0495US9499603B2PD-1 antibodiesUCB BIOPHARMA SPRL·Filed 2015·Granted Nov 22, 2016·19 cites·5 claims
- 0595US9102728B2PD-1 antibodiesTYSON KERRY LOUISE·Filed 2011·Granted Aug 11, 2015·45 cites·23 claims
- 0695US8784823B2Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereofUCB PHARMA SA·Filed 2012·Granted Jul 22, 2014·38 cites·7 claims
- 0795US8293237B2Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereofBURKLY LINDA C·Filed 2008·Granted Oct 23, 2012·40 cites·19 claims
- 0893US10618957B2Antibody molecules which bind CD79UCB BIOPHARMA SPRL·Filed 2016·Granted Apr 14, 2020·9 cites·12 claims
- 0993US10370447B2Molecules with specificity for CD79 and CD22UCB BIOPHARMA SPRL·Filed 2015·Granted Aug 6, 2019·15 cites·11 claims
- 1091US11472879B2Antibody molecules which bind CD22UCB Biopharma SRL·Filed 2020·Granted Oct 18, 2022·2 cites·20 claims
- 1190US10774152B2Molecules with specificity for CD45 and CD79UCB BIOPHARMA SPRL·Filed 2015·Granted Sep 15, 2020·5 cites·12 claims
- 1288US11261242B2Anti-alpha-synuclein antibodiesUCB Biopharma SRL·Filed 2018·Granted Mar 1, 2022·3 cites·21 claims
- 1388US11014979B2Anti-AP2 antibodies and antigen binding agents to treat metabolic disordersHARVARD COLLEGE·Filed 2018·Granted May 25, 2021·4 cites·35 claims
- 1488US10233243B2Anti-FcRn antibodiesUCB BIOPHARMA SPRL·Filed 2013·Granted Mar 19, 2019·10 cites·17 claims
- 1587US11261252B2Molecules with specificity for CD79 and CD22UCB Biopharma SRL·Filed 2019·Granted Mar 1, 2022·2 cites·10 claims
- 1686US10344081B2Tau-binding antibodiesUCB BIOPHARMA SPRL·Filed 2016·Granted Jul 9, 2019·3 cites·38 claims
- 1785US12247068B2Anti-AP2 antibodies and antigen binding agents to treat metabolic disordersHARVARD COLLEGE·Filed 2021·Granted Mar 11, 2025·1 cites·19 claims
- 1883US10906966B2Tau-binding antibodiesUCB Biopharma SRL·Filed 2019·Granted Feb 2, 2021·1 cites·19 claims
- 1983US9683043B2PD-1 specific antibodies and uses thereofISIS INNOVATION·Filed 2015·Granted Jun 20, 2017·4 cites·14 claims
- 2083US2025346672A1Anti-fcrn antibodiesUCB Biopharma SRL·Filed 2025·Application pending·0 cites
- 2182US10273302B2Antibodies specific to FcRnUCB BIOPHARMA SPRL·Filed 2014·Granted Apr 30, 2019·5 cites·22 claims
- 2282US10160798B2Anti-aP2 antibodies and antigen binding agents to treat metabolic disordersHARVARD COLLEGE·Filed 2016·Granted Dec 25, 2018·4 cites·48 claims
- 2381US9957320B2Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13UCB BIOPHARMA SPRL·Filed 2016·Granted May 1, 2018·3 cites·8 claims
- 2480US12338285B2Anti-FcRn antibodiesUCB Biopharma SRL·Filed 2022·Granted Jun 24, 2025·0 cites·52 claims
- 2580US11384148B2Anti-FcRn antibodiesUCB BIOPHARMA SPRL·Filed 2019·Granted Jul 12, 2022·1 cites·16 claims
- 2680US9394361B2Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13UCB PHARMA SA·Filed 2014·Granted Jul 19, 2016·4 cites·9 claims
- 2780US2023331833A1Tau-binding antibodiesUCB Biopharma SRL·Filed 2023·Application pending·0 cites
- 2880US2023135399A1Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereofUCB Biopharma SRL·Filed 2022·Application pending·0 cites
- 2979US12331117B2Antibody molecules which bind CD22UCB Biopharma SRL·Filed 2022·Granted Jun 17, 2025·0 cites·20 claims
- 3079US9321840B2Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereofUCB PHARMA SA·Filed 2014·Granted Apr 26, 2016·2 cites·15 claims
- 3179US8691233B2Antibody molecules having binding specificity for human IL-13GOZZARD NEIL·Filed 2010·Granted Apr 8, 2014·7 cites·12 claims
- 3274US11292831B2Anti-alpha synuclein antibodiesUCB Biopharma SRL·Filed 2018·Granted Apr 5, 2022·1 cites·21 claims
- 3374US10766956B2Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosisUCB BIOPHARMA SPRL·Filed 2017·Granted Sep 8, 2020·1 cites·11 claims
- 3474US9249232B2Framework selectionADAMS RALPH·Filed 2007·Granted Feb 2, 2016·1 cites·10 claims
- 3573US11746145B2Tau-binding antibodiesUCB Biopharma SRL·Filed 2020·Granted Sep 5, 2023·0 cites·18 claims
- 3673US2025346654A1Anti-ap2 antibodies and antigen binding agents to treat metabolic disordersHARVARD COLLEGE·Filed 2025·Application pending·0 cites
- 3771US2023287134A1Antibody molecules which bind cd45UCB Biopharma SRL·Filed 2023·Application pending·0 cites
- 3869US2022162311A1Antibodies specific to fcrnUCB BIOPHARMA SPRL·Filed 2021·Application pending·0 cites
- 3966US11220547B2Antibodies specific to FCRNUCB BIOPHARMA SPRL·Filed 2019·Granted Jan 11, 2022·0 cites·52 claims
- 4066US2019233530A1Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereofUCB BIOPHARMA SPRL·Filed 2019·Application pending·0 cites
- 4163US12410244B2Anti-alpha-synuclein antibodiesUCB Biopharma SRL·Filed 2022·Granted Sep 9, 2025·0 cites·15 claims
- 4259US7273744B2Heparanase-like polypeptidesUCB PHARMA SA·Filed 2002·Granted Sep 25, 2007·1 cites·3 claims
- 4358US11692041B2Antibody molecules which bind CD45UCB BIOPHARMA SPRL·Filed 2016·Granted Jul 4, 2023·0 cites·14 claims
- 4458US11518803B2Antagonist antibodies that bind to human TGFB1, TGFB2 and to TGFB3 and their use for the treatment of lung fibrosisUCB Biopharma SRL·Filed 2020·Granted Dec 6, 2022·0 cites·20 claims
- 4558US2023075753A1Antibodies against klk5UCB Biopharma SRL·Filed 2021·Application pending·0 cites
- 4658US2016200823A1Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereofUCB PHARMA SA·Filed 2016·Application pending·0 cites
- 4756US2025026836A1Anti-hla-g antibodiesUCB Biopharma SRL·Filed 2022·Application pending·0 cites
- 4855US2023070261A1Antibodies against klk5UCB Biopharma SRL·Filed 2021·Application pending·0 cites
- 4953US2019359713A1Molecules with specificity for cd45 and cd79UCB BIOPHARMA SPRL·Filed 2019·Application pending·0 cites
- 5053US2020377578A1Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficileUCB BIOPHARMA SPRL·Filed 2020·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Kerry Louise Tyson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →